# L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

> **NCT05775705** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 25 (estimated)

## Conditions studied

- PD-1 Antibody
- Hemophagocytic Lymphohistiocytosis
- Epstein-Barr Virus
- Lymphoma

## Interventions

- **DRUG:** L-DEP and PD-1 antibody

## Key facts

- **NCT ID:** NCT05775705
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775705, "L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05775705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*